Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

VYNEVery BearishCorporate Developmentsnews

High materiality10/10

FDA Puts VYNE Therapeutics Early-Stage Psoriasis Study On Hold

Apr 25, 2025, 12:17 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The FDA clinical hold signifies serious regulatory concerns, negatively affecting investor confidence. Historically, similar holds have led to significant stock price declines in biotech companies.

AI summary

What happened, with direct paths to the underlying reporting

FDA placed a clinical hold on VYNE's VYN202 Phase 1b study. Hold due to testicular toxicity observed in dogs during toxicity studies. VYNE has suspended screening, enrollment, and dosing related to VYN202. No serious adverse events reported in the Phase 1b study so far. VYNE continues Phase 2b trial of repibresib, unrelated to VYN202.

FDA placed a clinical hold on VYNE's VYN202 Phase 1b study.
Hold due to testicular toxicity observed in dogs during toxicity studies.
VYNE has suspended screening, enrollment, and dosing related to VYN202.
No serious adverse events reported in the Phase 1b study so far.
VYNE continues Phase 2b trial of repibresib, unrelated to VYN202.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.